Dermatological Assessment of Photoallergy and Phototoxicity

• Agreement to comply with safety guidelines to minimize the risk of contamination to COVID-19;
• Agreement to perform a molecular test for the detection of COVID-19 to enter the study;
• Healthy participants;
• Non-injured skin in the test region;
• Agreement to adhere to the test procedures and requirements and to attend the institute on the day(s) and at the time(s) determined for the evaluations;
• Ability to consent to participation in the study;
• Age from 18 to 70 years;
• Phototype (Fitzpatrick): II and III;
• Any gender

Exclusion Criteria:

• Participants who belong to the risk group for COVID-19, that is, with diabetes, with chronic cardiovascular, renal and respiratory problems, immunosuppressed or other conditions that the physician deems as belonging to the risk group;
• Skin marks in the experimental area;
• Active dermatoses (local or widespread);
• Pregnant or breastfeeding women;
• History of allergic reactions, irritation or intense feelings of discomfort to topical products;
• History of phototoxic or photoallergic reactions;
• History of allergy to materials used in the study;
• History of atopy;
• Personal or family pathological history of skin cancer;
• History of pathologies aggravated or triggered by ultraviolet radiation;
• Carriers of immunodeficiencies;
• Intense sun exposure or tanning session up to 15 days before the initial evaluation;
• Predicted intense sun exposure or tanning session during the course of the study;
• Predicted bathing in the sea, pool or bathtub during the study;
• Participants who practice water sports;
• Dermography;
• Use of the following topical or systemic drugs: immunosuppressants, antihistamines, non-hormonal anti-inflammatory drugs and corticoids up to 2 weeks prior to selection or, considering deposit corticoids, the interval shall be 1 month prior to selection;
• Use of topical or systemic photosensitizing drugs;
• Treatment with acid vitamin A and/or its derivatives via oral or topical until 1 month before the beginning of the study;
• Aesthetic and/or body dermatological treatment until 3 weeks before selection;
• Vaccination during the study or until 3 weeks before the study;
• Being or having participated in another clinical trial terminated less than 7 days before selection, in case the previous trial is acceptable in use;
• Being or having participated in another clinical trial terminated less than 21 days ago, in case the previous trial is compatible or Adverse Reaction investigative;
• History of absence of adherence or unwillingness to adhere to the study protocol;
• Professionals directly involved in the execution of this protocol and their relatives.
• Participants who have COVID-19, or who present symptoms indicative of the disease in the last 14 days.
• Any condition not mentioned above that, in the opinion of the investigator, may compromise the evaluation of the study.